Antimicrobial activity of different Lactobacillus species against multi-drug resistant clinical isolates of Pseudomonas aeruginosa
-
H Jamalifar
,
HR Rahimi
,
N Samadi
,
AR Shaverdi
,
Z Sharifian
,
F Hosseini
,
H Eslahi
,
MR Fazeli
Abstract
Background: Lactobacilli are the well known friendly bacteria for their probiotic activities against pathogens. The inhibitory activity of different strains of lactobacilli either obtained as commercial products or isolated from human feces was investigated against the clinical isolates of Pseudomonas aeruginosa. The isolates were selected as the most resistant strains when challenged with anti-pseudomonal antibiotics already in clinical practice.
Materials and Methods: Both the plate spot test as well as the agar cup method were used for screening of Lactobacillus strains against Pseudomonas aeruginosa.
Results: A Lactobacillus acidophilus strain isolated from feces of an Iranian child showed a strong anti-pseudomonal activity (90 percent after 72h incubation) against the multi-drug resistant clinical isolates while a Lactobacillus reuteri strain isolated from a commercial oral product resulted in relatively weak response and a Lactobacillus acidophilus strain isolated from a commercial vaginal product did not show any inhibitory activity. In a kinetic study the lactobacillus sensitive Pseudomonas aeruginosa showed a significant bacteriostatic activity in vitro in the presence of lactobacillus supernatants.
Conclusion: Some lactobacilli exhibit significant inhibitory activity against the multidrug resistant clinical isolates of Pseudomonas aeruginosa.
Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB, et al. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997;28: 211-219.
Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29:19-24.
Vosahlikova S, Drevinek P, Cinek O, Pohunek P, Maixnerova M, Urbaskova P, et al. High genotypic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis in the Czech Republic. Res in Microbiol 2007; 158: 324-329.
Brook I. Otitis media: microbiology and management.J Otolaryngol 1994; 23: 269-275.
Lyczak, JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2000; 2: 1051-1060.
Burgess DS. Use of pharmacokinetics and pharma- codynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 2: S99-104.
Paul R. Rhomberg, Ronald N. Jones, Helio S. Sade.Results from the meropenem yearly susceptibility test information collection (MYSTIC) programme: report of the 2001 data from 15 United States medical centers. Int J Antimicrob Agents 2004; 23: 52-59.
Patzer JA, Dzier˙zanowska d. Increase of imipenem resistance among Pseudomonas aeruginosa isolates from a Polish pediatric hospital (1993–2002). Int J Antimicrob Agents 2007; 29: 153-158.
Gordon D, Macrae J, Wheater DM. A lactobacillus preparation for use with antibiotics. Lancet 1957; 272:899-901.
Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993; 12: 221-238.
Carson CF, Riley TV. Non-antibiotic therapies for infecti- ous diseases. Commun Dis Intell 2003; 27: 143-146.
Gibbs PA. Novel uses for lactic acid fermentation in food preservation. J Appl Bacteriol Symp Suppl 1987;63: 51S-58S.
Perry JD, Laine L, Hughes S, Nicholson A, Galloway A, Gould FK. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J Antimicrob Chemother 2008; 61: 1057-61.
Pinto AL, Fernandes M, Pinto C, Albano H, Castilho F, Teixeira P, et al. Characterization of anti-Listeria bacteriocins isolated from shellfish: potential antimicrobials to control non-fermented seafood. Int J Food Microbiol 2009; 129: 50-8.
Jiang X, Zhang Z, Li M, Zhou D, Ruan F, Lu Y.Detection of extended-spectrum β-Lactamases in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agts Chemother 2006; 50: 2990-2995.
Shannon KP and French GL. Increasing resistance to antimicrobial agents of Gram-negative organisms isolated at a London teaching hospital, 1995–2000. J Antimicrob Chemother 2004; 53: 818-825.
Johann DDP, Barbara LC, Daniel BG, Kevin BL, Sameer E, Deirdre LC. Molecular epidemiology of metallo-ß- lactamase-producing Pseudomonas aeruginosa in the Calgary health region: Emergence of VIM-2-producing isolates. J Clin Microbiol 2007; 45: 294-298.
Victor Lorian. Antibiotics in laboratory medicine. 5rd ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 12-85.
Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43: 287-291.
Engel LS, Callegan MC, Hill JM, Richard J. Bioassays for quantitating ciprofloxacin and tobramycin in aque- ous humor. J Ocul Pharmacol 1993; 9: 311-320.
Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant Gram-negative bacilli in North America. Pharmacotherapy 2008; 28: 235-249.
Souli M, Galani I, Giamarellou H. Emergence of extensively drug resistant and pan-drug-resistant Gram- negative bacilli in Europe. Euro surveill 2008; 13:1-11.
Siegel RE. Emerging Gram-negative antibiotic resistance: daunting challenges, declining sensitivity, and dire consequences. Respir Care 2008; 53: 471-479.
Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug resistant Gram- negative bacilli. Antimicrob Agents Chemother 2008;52: 813-821.
Slama TG. Gram-negative antibiotic resistance: there is a price to pay. Crit Care 2008; 12: 233-239.
Chopra I, Schofield C, Everett M, O’Neill A, Miller K, Wilcox M, et al. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consens- us statement. Lancet Infect Dis 2008; 8:133-139.
Antonio MAD, Hawes SE, Hillier SL. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 1999; 180: 1950-1956.
Redondo-Lo´pez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990; 12:856-872.
Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004; 28: 405-440.
Mcfarland LV. Normal flora: diversity and functions.Microb Ecol Health Dis. 2000; 12: 193-207.31. Reid G, Burton J. Use of lactobacillus to prevent Infection by pathogenic bacteria . Microbes infection.2002; 4: 319-24.
Gill H.S, Rutherfurd K.J, CrossM.L, Gopal P.K. Enhance- ment of immunity in the elderly by dietary supplementa- tion with the probiotic Bifidobacterium lactis HN019 Am J Clin Nutr 2001; 74: 833-839.
Osset J, Bartolomé RM, García E, Andreu A. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis 2001; 183: 485-491.
Baerheim A, Larsen E, Digranes A. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand J Prim Health Care 1994; 12: 239-43.35. Reid G, Millsap K, Bruce AW. Implantation of Lactobacillus casei var. rhamnosus into vagina. Lancet 1994; 344: 1229.36. Bruce AW, Reid G. Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections. Can J Microbiol 1988; 34: 339-43.
Reid G, Bruce AW, Taylor M. Influence of three- day antimicrobial therapy and Lactobacillus vaginal suppositories on recurrence of urinary tract infection. Clin Ther 1992; 14: 11-16.
| Files | ||
| Issue | Vol 3 No 1 (2011) | |
| Section | Articles | |
| Keywords | ||
| Lactobacillus species Anti pseudomonal activity Pseudomonas aeruginosa | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
